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Novelty and Impact Statements 
This is the first dose-response meta-analysis on the relationship between calcium intake and 
colorectal adenomas.  By showing a continued reduction in risk of adenomas, particularly high-
risk adenomas ( ≥ 1 cm in diameter, (tubulo)villous histology, dysplasia, or multiplicity), beyond 
1,000 mg/day of total calcium intake, our results suggest that calcium may have 
chemopreventive potential against colorectal neoplasia, irrespective of baseline total calcium 
intake over a wide range. 
 
 
 
Abstract 
Evidence from randomized controlled trials suggests that calcium may protect against recurrence 
of colorectal adenomas, which could lead to the subsequent prevention of cancer.  Yet, because 
the trials used only a large single dose and were of small sizes, knowledge of the dose-response 
relationship and influence on high-risk adenomas is limited.  To address these issues, we 
conducted linear and non-linear dose-response meta-analyses primarily based on prospective 
observational studies published up to July 2014 identified from PubMed and Embase.  Summary 
relative risks (RRs) and 95% confidence intervals (CIs) were calculated for total and 
supplemental calcium intake, respectively, using a random-effects model.  For total calcium 
intake, summary RR for each 300mg/day increase was 0.95(95% CI=0.92-0.98; I
2
=45%; 8 
studies with 11,005 cases; range of intake=333-2,229 mg/day).  Evidence of non-linearity was 
indicated: approximately, compared to 550 mg/day of total calcium intake, the summary RR was 
0.92(95% CI=0.89-0.94) at 1000 mg/day and 0.87(95% CI=0.84-0.90) at 1450 mg/day (Pnon-
linearity<0.01).  Associations were stronger for high-risk adenomas (≥1 cm in diameter, 
(tubulo)villous histology, dysplasia, or multiplicity): approximately, compared to 550 mg/day of 
total calcium intake, the summary RR was 0.77(95% CI=0.74-0.81) at 1000 mg/day and reduced 
to 0.69(95% CI=0.66-0.73) at 1450 mg/da (Pnon-linearity<0.01).  For supplemental calcium intake, 
summary RR of total adenoma risk for each 300mg/day increase was 0.96(95% CI=0.93-0.99; 
I
2
=0%; 3 studies with 4,548 cases; range of supplementation=0-1,366 mg/day).  In conclusion, 
calcium intake may continue to decrease the risk of adenomas, particularly high-risk adenomas, 
over a wide range of calcium intake.   
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Introduction 
 Colorectal cancer is the third most commonly diagnosed cancer and the fourth leading 
cause of cancer death worldwide, excluding non-melanoma skin cancer.
1
  The majority of 
colorectal cancers are preceded by adenomas
2
 and thus, targeting adenomas is an effective way 
to prevent colorectal cancer.  While screening endoscopy that detects and removes asymptomatic 
adenomas has been suggested to reduce colorectal cancer incidence rates and mortality
3, 4
, a 
significant proportion of people with initial adenomectomy develop recurrent adenomas within 
three years.
5
  Thus, there is a pressing need to identify modifiable factors that could reduce the 
risk of adenoma occurrence (first time diagnosis of adenomas) and recurrence (development of 
adenomas after undergoing previous adenomectomy). 
 Available evidence suggests that calcium may have chemopreventive potential against 
adenomas.  In a meta-analysis of three randomized controlled trials (RCTs), compared to people 
assigned to a placebo group, those assigned to take 1,200-2,000 mg of calcium supplements 
without co-administered vitamin D over 3-4 years had an approximately 20% reduced risk of 
adenoma recurrence.
6
  Given that the beneficial effect manifested within a short duration of 
intervention and that the evidence came from RCTs, the current gold-standard study design for 
establishing a causal relationship, a role of calcium in the prevention of adenomas appears to be 
promising.   
 However, each of the RCTs included tested only a large dose of supplemental calcium 
and thus, critical information in developing guidelines for chemoprevention by calcium, such as 
the dose-response relationship, is missing.  Given some concern on the suggested harm of high-
dose calcium supplements on cardiovascular disease,
7, 8
 identification of the dose-response 
relationship would also help answer an important clinical question if regular use of low-dose 
calcium supplements could lead to protection against adenomas and thus, ultimately, colorectal 
cancer.  Moreover, the propensity of adenomas to progress, left unremoved, varies greatly by 
size, histology, grade and number.
2
  While the Calcium Polyp Prevention Study suggested a 
greater benefit for high-risk adenomas,
9
 the majority of endpoints in the trials of recurrent 
adenomas were likely to be solitary, small tubular adenomas, which have a low propensity to 
progress.
2
  Thus, we conducted a dose-response meta-analysis of prospective observational 
studies, addressing potential heterogeneity in the relationship by adenoma subtypes.  
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Methods 
 For the design, analysis, and reporting of this study, the Meta-analysis Of Observational 
Studies in Epidemiology (MOOSE) checklist
10
 was followed for meta-analysis of prospective 
observational studies.  Two authors (DL and NK) participated in literature search, study selection, 
and data extraction independently.  Inconsistency between researchers was resolved through 
discussion. 
 
Literature Search 
 PubMed and Embase databases were searched for studies published up to July 2014. 
Detailed search terms are provided (Supplementary Table 1).  The language was limited to 
English and no other restrictions were imposed.  Abstracts and unpublished results were not 
included.  The reference lists of selected reviews and meta-analyses, and all the articles included 
in our analysis were also reviewed for additional studies. 
 
Study Selection 
 To be included, studies had to be an observational study (e.g. cross-sectional, case-
control, or cohort study) investigating the relationship between calcium intake and colorectal 
adenomas.  For dose-response meta-analysis, studies had to provide the following information: a 
quantitative measure of calcium intake for at least 3 categories with the estimates of RRs (odds 
ratio, rate ratio, or hazard ratio), 95% confidence interval (CI), category-specific or total number 
of cases, and category-specific or total number of either noncases or person-years.  When there 
were several publications from the same cohort, the publication with the largest number of cases 
was selected.  Authors of two cohort studies
11, 12
 were contacted for additional data and one
11
 of 
the two studies could be incorporated in dose-response meta-analysis.  The procedure of study 
selection, including reasons for exclusion, is summarized in Figure 1. 
 
 
Data Extraction  
 From each study, the following information was extracted: the most fully adjusted RR 
and corresponding 95% CI in each category of calcium intake, category-specific range of 
calcium intake, category-specific or total number of cases, category-specific or total number of 
person-years (for rate ratio or hazard ratio) or noncases (for odds ratio), types of calcium intake 
(total=dietary+supplemental, dietary, supplemental), mean or median calcium intake of source 
population at study entry, subtypes of adenomas by anatomic location and propensity to progress 
to colorectal cancer (high risk adenoma characterized by large size of ≥ 1 cm in diameters, 
(tubulo)villous histology, dysplasia, or multiplicity vs. small adenomas), first author's name, 
publication year, study design, study name, country of the study population, sex, age at 
enrollment, sample size, number of cases, study period, dietary assessment method (type, 
whether it had been validated), adjustment variables, temporality (i.e. prospective: diet was 
assessed prior to participants' knowledge of adenoma status; retrospective: diet was assessed 
prior to participants' knowledge of adenoma status).  
 
Statistical Analysis 
 Across cross-sectional, case-control, or cohort studies, cohort studies are generally least 
prone to biases.  However, the asymptomatic nature of adenomas reduced methodological 
distinctions across the study designs in the investigation of calcium intake and adenoma risk.  
For instances, as the true case and control status can be determined only at time of endoscopy, 
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most studies defined the source population as subjects who underwent an endoscopy. 
Furthermore, as the timing of endoscopy was not necessarily guided by symptoms, time from 
study baseline to adenoma detection is rather arbitrary.  Thus, like the other study designs, most 
cohort studies used logistic regression only accounting for whether or not an event happens 
rather than Cox regression incorporating both whether or not and when an event happens.  For 
these reasons, one of the most important methodological distinctions narrowed down to temporal 
relationship between the assessment of calcium intake and participants' knowledge about their 
adenoma status.  As studies that prospectively assessed calcium intake are less prone to recall 
bias than those that retrospectively assessed, prospective studies constituted our primary analysis.   
 Furthermore, out of the three possible types of calcium intake (total, dietary, 
supplemental), total calcium intake is the exposure measure that is most relevant to exploring a 
dose-response relationship between calcium intake and adenoma risk.  Thus, our primary meta-
analysis included prospective studies that investigated total calcium intake.  To enhance the 
comparability of our results with RCTs that tested the effect of supplemental calcium, a dose-
response meta-analysis was also conducted based on prospective studies that investigated 
supplemental calcium.   
 Linear and non-linear dose-response meta-analyses were conducted.  For linear dose-
response meta-analysis assuming a linear relationship between calcium intake and adenoma risk, 
the method described by Greenland and Longnecker
13
 was used to calculate study-specific RRs 
(linear slopes) and 95% CIs from the correlated RRs and 95% CIs extracted across categories of 
calcium intake.  In estimating study-specific linear trends, several approximations were made: 
the midpoint of calcium intake in each category was assigned to the corresponding RR; the width 
of the open-ended extreme categories was assumed to be the same as that of the adjacent 
interval; when the distributions of person-years or non-cases were not provided but analyzed 
based on quantiles, they were equally divided across the quantiles; for studies
14, 15
 that showed 
results separately for distal and rectal adenomas or for men and women, category-specific RRs 
and variances were combined using a fixed effects model based on inverse variance weight to 
obtain combined estimates for colorectal adenomas or for both sexes, before estimating the 
study-specific RR and 95% CI; for one study
16
 that used the sixth lowest category of calcium 
intake as the reference, the method by Hamling et al
17
 was used to estimate new RRs and 95% 
CIs setting the lowest category as the new reference.  Then, the estimated study-specific RRs and 
variances were pooled using a random effects model to calculate the summary RR and 95% CI.  
Forest plots of the linear dose-response meta-analysis were presented for RRs for each 
300mg/day increment of calcium intake (the unit equivalent to calcium content in one serving 
(250 mL) of milk).   
  To examine potential non-linear relationship between calcium intake and adenoma risk, 
non-linear dose-response meta-analysis was performed based on the restricted cubic spline 
approach.
18, 19
  Of note, this approach requires that studies have more than three categories of 
calcium intake.  For each study, cubic splines were modeled with three knots fixed at percentiles 
(10%, 50%, and 90%) of the whole distribution of calcium intake, accounting for correlation 
across category-specific RRs and 95% CIs within each study.
18
  The reference was set to 550 
mg/day, the lowest value of the reported calcium intakes that were concentrated in lower 
extremes.  Then, the derived curves were combined using multivariate random-effects meta-
analysis.
20
  The p-value for nonlinearity was obtained from the test of the null hypothesis that the 
regression coefficient of the second spline transformation was equal to zero.   
 Heterogeneity in the relationship between calcium intake and adenomas across studies 
was assessed by I
2 
and Q test.
21
  Subgroup analyses and meta-regression were conducted by a 
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priori selected variables related to etiologic heterogeneity and potential effect modifiers to 
identify sources of heterogeneity; by variables concerning methodological characteristics to 
assess study quality.  Potential for small study effects,
22, 23
 such as publication bias, was assessed 
visually using funnel plots and statistically using Egger's test.
24
  Upon the detection of 
statistically significant evidence of small study effects, contour-enhanced funnel plot was plotted 
that distinguishes areas of the statistical significance and non-significance of the funnel plot 
using contour.
25, 26
  By presenting each study in the context of statistical significance, this plot 
helps determine if the cause of asymmetry is attributable to publication bias based on statistical 
significance.
25
  To explore robustness of the results, diverse sensitivity analyses including the 
influence analysis and highest vs. lowest meta-analysis that pooled RRs for the extreme 
categories of calcium intake using a random effects model were performed.  For statistical 
significance, two-sided α was set at P=0.05.  All statistical analyses were conducted using 
STATA 12 (StataCorp, College Station, TX). 
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Results 
 
Total calcium intake     
 A total of 14 studies
11, 14-16, 27-36
 were eligible for the inclusion in dose-response meta-
analysis of total calcium intake and adenoma risk (Supplementary Table 2).  Across the studies, 
types of adenomas investigated varied.  The study by Lieberman et al.
27
 specifically investigated 
advanced adenomas and the other 13 studies primarily examined total adenomas with some 
studies
11, 16, 27, 29, 34, 35
 further conducting subgroup analysis by adenoma subtypes.  Two studies
35, 
36
 exclusively investigated recurrent adenomas and the other 12 studies examined occurrent 
adenomas.  While accumulating evidence suggests that calcium may be more protective against 
advanced adenomas,
9, 11, 16, 29, 35
 there is no sufficient a priori evidence to suspect that the effect 
of calcium may differ by recurrent vs. occurrent adenomas.  Thus, dose-response meta-analysis 
of total calcium intake and adenoma risk was based on 13 studies
11, 14-16, 28-36
 excluding the study 
by Lieberman et al.,
27
 which was included only in the subgroup analysis for high-risk adenomas. 
  Out of the 13 studies,
11, 14-16, 28-36
 eight studies
11, 14, 16, 29, 31, 34-36
 qualified for prospective 
studies, including a total of 11,005 cases with category-specific midpoints of total calcium intake 
ranging from 333 to 2,229 mg/day; the remaining five studies were classified as retrospective 
studies (2,401 cases, range=285-1405 mg/day). 
 In the linear dose-response meta-analysis of eight prospective studies,
11, 14, 16, 29, 31, 34-36
 
each 300 mg/day increase in total calcium intake was associated with an approximately 5% 
decreased risk of adenomas (RR=0.95, 95% CI=0.92-0.98), with moderate heterogeneity 
(I
2
=45%, Pheterogeneity=0.08) (Figure 2A).  The linear association was stronger among retrospective 
studies (RR=0.91, 95% CI=0.82-1.01), but it was not statistically significant and had a greater 
degree of heterogeneity (I
2
=58%, Pheterogeneity=0.05) (Figure 2B).  There was no evidence of 
heterogeneity by prospective vs. retrospective assessment of calcium intake (Pheterogeneity=0.67).  
In sensitivity analyses such as excluding one study at a time and including one additional 
prospective studies
37
 that reported dietary calcium intake instead of total calcium intake, the 
results did not change materially (data not shown).   
 In the non-linear dose-response meta-analysis, after excluding one study
31
 that analyzed 
calcium intake in three categories only, seven prospective studies
11, 14, 16, 29, 34-36
 were included 
(10,828 cases, range=333-2,229 mg/day).  Moderate non-linearity was apparent, with adenoma 
risk decreasing more steeply in the lower range of total calcium intake than in the higher range 
(Pnon-linearity<0.01) (Figure 3A).  Approximately, compared to 550 mg/day of total calcium intake, 
the summary RR was 0.92 (95% CI=0.89-0.94) at 1000 mg/day and further reduced to 0.87 (95% 
CI=0.84-0.90) at 1450 mg/day.      
 Although the number of prospective studies was limited, small study effects, such as 
publication bias, were indicated by asymmetry in the funnel plot and Egger's test 
(P<0.01)(Figure 4).  Several sensitivity analyses were performed.  First, when an equivalent 
analysis was run using a fixed effects model, which gives less weight to small studies compared 
to a random effects model, the association was attenuated but still statistically significant 
(RR=0.96, 95% CI=0.95-0.98, I
2
=45%, Pheterogeneity=0.08).  Second, contour-enhanced funnel plot 
indicated that potential missing studies were likely to be located in both statistically significant 
and non-significant areas, reducing the possibility of publication bias based on statistical 
significance to explain the observed asymmetry (Figure 4).  Third, when highest vs. lowest meta-
analysis was performed including two additional prospective studies
12, 37
 that were not eligible 
for dose-response analysis due to insufficient information, a significant inverse association 
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persisted (RR=0.84, 95% CI=0.78-0.92) with no evidence of heterogeneity (I
2
=0%, 
Pheterogeneity=0.47) and no evidence of small study effects(PEgger=0.35) (Supplementary Figure 1). 
 To explore if the inverse association with calcium was stronger against high-risk 
adenomas than against other subtypes, subgroup analysis was performed by differential 
propensity to progress to colorectal cancer.  Consistent with the prior evidence,
9, 11, 16, 29, 35
 the 
linear association was stronger with high-risk adenomas (RR=0.89, 95% CI=0.85-0.94, I
2
=17%, 
Pheterogeneity=0.30, 6 prospective studies
11, 16, 27, 29, 34, 35
 with 2,685 cases, range=333-1,822 mg/day) 
than with small adenomas (RR=0.97, 95% CI=0.94-1.01, I
2
=0%, Pheterogeneity=0.91, 3 prospective 
studies
11, 16, 29
 with 3,540 cases, range=333-1,822 mg/day) (Figure 2B).  Between-subgroup 
heterogeneity by high-risk vs. small adenomas was statistically significant (Pheterogeneity=0.02).  
When the non-linear dose-response curve was plotted among high-risk adenomas (Pnon-
linearity<0.01) (Figure 3B), the overall slope was much steeper compared with that for total 
adenomas.  Approximately, compared to 550 mg/day of total calcium intake, the summary RR 
was 0.77 (95% CI=0.74-0.81) at 1000 mg/day and further reduced to 0.69 (95% CI=0.66-0.73) at 
1450 mg/day.     
 
Supplemental calcium intake  
 Out of the eight prospective studies
11, 14, 16, 29, 31, 34-36
 included in the meta-analysis on total 
calcium intake, three studies
14, 35, 36
 reported sufficient information for dose-response meta-
analysis of supplemental calcium intake and adenoma risk.  All of the three studies were from 
the U.S. where supplement usage is relatively high. They included a total of 4,548 cases with 
category-specific midpoints of supplemental calcium intake ranging from 0 to 1,366 mg/day 
(Supplementary Table 2).  In the linear dose-response meta-analysis, each 300 mg/day increase 
in supplemental calcium intake was associated with an approximately 4% decreased risk of 
adenomas (RR=0.96, 95% CI=0.93-0.99), with no evidence of heterogeneity (I
2
=0%, 
Pheterogeneity=0.53) (Figure 2C).  The small number of studies included precluded a meaningful 
influence analysis.  Albeit low-powered due to the small number of studies included, Egger's test 
provided no evidence of small study effects, such as publication bias (P=0.44).  The funnel plot 
also displayed a symmetrical shape.  Non-linear dose-response meta-analysis was not conducted, 
as two out of the three studies had only three categories of calcium intake and thus were not 
eligible for the restricted cubic spline approach. 
 
Subgroup analyses 
 For the linear dose-response meta-analysis of total calcium intake and adenomas based on 
the eight prospective studies,
11, 14, 16, 29, 31, 34-36
 subgroup analyses were performed to explore 
sources of the observed moderate heterogeneity (Supplementary Table 3).  A statistically 
significant inverse association persisted in most of the subgroups, suggesting robustness of the 
inverse association.  There was evidence of between-subgroup heterogeneity by number of cases 
(Pheterogeneity=0.03), with a stronger inverse association observed in the subgroup of studies with 
≤1000 cases of adenomas.  This is consistent with the observed evidence of small study effects, 
but an inverse association was still statistically significant in the subgroup of studies with >1000 
cases of adenomas.  The magnitude of an inverse association was similar regardless of 
adjustment for confounding by vitamin D status (determined by intake or sun exposure). 
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Discussion 
 In our dose-response meta-analyses of prospective observational studies, each 300 
mg/day increase in total calcium intake was associated with an approximately 5% decreased risk 
of adenoma occurrence/recurrence within the 333-2,229 mg/day range of total calcium intake.  
While a non-linear dose-response relationship was indicated with adenoma risk decreasing less 
steeply at higher levels of calcium intake, the degree of curvature was mild and thus, overall, a 
linear association reasonably approximated the shape of the relationship.  The linearity was 
further supported by the subgroup analyses that showed equivalent results between two 
subgroups classified by mean/median baseline calcium intakes of study populations.  Of note, a 
stronger association was observed for high-risk adenomas having a high propensity to progress 
to colorectal cancer, with an 11% reduction in adenoma risk for each 300 mg/day increase in 
calcium intake.  This magnitude of risk reduction is consistent with the results of our previous 
linear dose-response meta-analysis that found a 8% decreased risk of colorectal cancer associated 
with each 300 mg/day increase in calcium intake.
38
  
 The strength of the linear association might have been overestimated due to small study 
effects, but several lines of evidence suggest robustness of the quantitative finding.  First, in the 
dose-response meta-analysis of supplemental calcium intake in which no evidence of small study 
effects was found, results were virtually the same (RR=0.96, 95% CI=0.93-0.99).  Second, in the 
meta-analysis
6
 of RCTs that compared calcium supplementations of 1200-2000 mg/day 
(weighted average: 1400 mg/day) with placebo, its pooled estimate of 20% reduction in adenoma 
risk is consistent with that estimated from our linear dose-response meta-analysis of prospective 
observational studies.  Given 4-5% reduction per 300 mg/day increase in calcium intake, 19-23% 
reduction in adenoma risk is predicted by 1400 mg/day difference in calcium intake.  
Considering that heterogeneity was low in each meta-analysis of prospective observational 
studies on supplemental calcium and of RCTs on calcium supplements, such consistency in 
estimates after accounting for dose of calcium intake serves as strong evidence for robustness of 
our quantification of the linear dose-response relationship. 
 The detailed investigations of the association over a wide range of calcium intake by 
adenoma subtypes, particularly among high-risk adenomas, distinguish our meta-analysis from 
the meta-analysis of RCTs.
6
  As adenomas are an etiologically heterogeneous disease with 
differential potential to progress colorectal cancer
2, 9
, a certain subtype could be more responsive 
to the chemopreventive effect of calcium.  In the meta-analysis of RCTs that included a total of 
407 adenomas, the power to perform subgroup analyses by adenoma subtypes was limited.  For 
instance, in their analysis confined to large adenomas (> 0.9 cm), the confidence interval was 
wide (RR=0.78, 95% CI=0.50-1.22).
6
  In contrast, our dose-response meta-analysis on high risk 
adenomas included 2,685 adenomas and showed a statistically significant association, which was 
more pronounced than the association with small tubular adenomas.  Furthermore, as the RCTs 
exclusively investigated recurrent adenomas, only the role of calcium intake after the diagnosis 
of an adenoma was able to be examined.  Although the pathophysiology of occurrent and 
recurrent adenomas is likely to overlap, there are some differences, for example, in bowel 
location propensity.
39
  In addition occurrent adenomas may better capture the effect of earlier 
dietary intake.  Our meta-analysis performed a subgroup analysis to examine occurrent 
adenomas separately and observed a potential benefit that earlier calcium intake may confer.  
 Findings from our meta-analysis may inform the role of calcium in the colorectal 
carcinogenesis.  In light of the well-established natural history of colorectal carcinogenesis by 
which the progression from the normal epithelium, to hyperproliferative epithelium, to aberrant 
cryptic foci, to small adenomas, to large adenomas, and finally to adenocarcinomas occurs over a 
Page 9 of 22
John Wiley & Sons, Inc.
International Journal of Cancer
10 
 
long duration, up to 30 to 40 years
2
, the presence of an inverse association between calcium and 
adenoma risk suggests that calcium may act on an early stage of the pathway.  The protective 
role of calcium in the prevention of adenomas is also supported by several biological 
mechanisms.  First, calcium in the colorectal lumen binds to and precipitates with secondary bile 
acids or ionized fatty acids, protecting the mucosa from their carcinogenic effects
40, 41
.  Second, 
calcium has been suggested to reduce cell proliferation and promote cell differentiation and 
apoptosis, as a rise in extracellular calcium leads to an increase in cytosol calcium concentration 
of colonic epithelia cells, which in turn modulates signaling pathways related to such cell 
cycles
42-45
.  Third, given that mutations in the APC/β-catenin pathway are a common early 
hallmark in the colorectal carcinogenesis and that calcium was shown to induce favorable 
changes in the APC/β-catenin pathway
46
, calcium may prevent the initiation of the neoplastic 
pathogenesis. 
  Our meta-analysis has several limitations.  First, the small number of prospective studies 
included precludes a definitive conclusion related to the shape of relationship and subgroup 
analyses.  The non-linearity is strongly driven by data points in extreme values of the exposure, 
but we had sparse data in the high extreme of calcium intake, as shown by inner ticks on the x 
axis in Figure 3.  Similarly, our subgroup analyses were low-powered to identify a statistically 
significant source of between-subgroup heterogeneity.  Second, as studies on dietary intake are 
prone to substantial measurement error, our meta-analyses were also affected by measurement 
error within each study included.  Additional measurement error was introduced due to 
assumptions inevitable in conducting dose-response meta-analyses, such as assigning midpoint 
of category-specific calcium intake to the corresponding RR and equating the width of open-
ended extreme categories with that of the adjacent interval.  While the direction of bias cannot be 
predicted, measurement error is generally anticipated to attenuate the true effect
47
, particularly 
since the dietary information was collected before participants’ knowledge of case status.  
Despite diverse sources of measurement error, bias due to small study effects discussed above 
and bias due to measurement error are anticipated to direct opposite, offsetting each other to 
some degrees.  Thus, our quantification of 5% reduced risk in adenoma risk for each 300 mg/day 
increase in calcium intake maybe a reasonable approximation.   
 Another limitation relates to the inclusion of prevalent cases, particularly in the 
occurrence studies.   As most participants did not systematically undergo baseline endoscopy, 
some of them might have been harboring asymptomatic adenomas.  Thus, the cases detected 
were likely to be a mixture of incident and prevalent adenomas.  Inclusion of prevalent cases 
elicits several concerns.  The first is survival bias, that is, less fatal disease subtypes are over-
represented because individuals with prevalent disease have to survive up to study baseline in 
order to be included.  However, as adenomas are benign by themselves, existing adenomas were 
unlikely to have affected survival up to the study baseline, ameliorating the concern.  Second, 
because the precise timing of the appearance of the adenoma is not known, the time relation 
between calcium intake and adenoma appearance is unclear.  However, considering that people's 
diet tend to track over time, it might be acceptable to assume that calcium intake measured at 
study baseline were likely to reflect distant past diet prior to adenoma initiation.  Furthermore, as 
the majority of adenomas are asymptomatic, existing adenomas would not have induced people 
to change their calcium intake, which diminishes the likelihood of reverse causation.  
 Our meta-analysis has several strengths as well. To the best of our knowledge, this is the 
first meta-analysis that identified and quantified the dose-response relationship between calcium 
intake and adenoma risk over the wide range of calcium intake.  By showing consistency 
between meta-analysis of cohort studies and that of RCTs in terms of magnitude after adjusted 
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for dose, direction, and statistical significance of the association, our study provides strong 
evidence supporting a protective role of calcium in the prevention of adenomas.  As our primary 
dose-response meta-analysis included only prospective studies, recall bias is unlikely to have 
biased the results.  Indeed, the stronger linear association observed among retrospective studies 
might have been driven by recall bias.  While case-control studies that assessed diet intake before 
endoscopy were parts of our primary dataset of the eight prospective studies, as both cases and 
controls were sampled from the well-defined primary source population of subjects who 
underwent an endoscopy, there is less potential for selection bias.  Although confounding cannot 
be entirely ruled out in observational studies, the observation of the association for total and 
supplemental calcium intake after adjustment for multiple factors and in diverse populations (e.g. 
North America, Europe, Asia) argues against a confounding factor.  Arguably, vitamin D might 
be the most likely confounder, but the results were similar across subgroups defined by 
adjustment for confounding by vitamin D status, for supplemental calcium intake, and in a 
European/Asian studies where milk is not systematically fortified with vitamin D. 
 In conclusion, within the range of 333-2,229 mg/day total calcium intake, the risk of 
adenomas continued to decrease with an increasing calcium intake.  Given the dose-response 
relationship and evidence from RCTs, calcium may be an effective chemopreventive agent 
against adenomas, particularly high-risk adenomas.  Despite the anticipated efficacy and 
affordability of calcium supplements, several questions remain to be answered before clinical 
recommendations are made widely.  Given a broadly linear association of calcium intake with 
adenoma risk, especially advanced adenomas, and possible harm of high-dose calcium 
supplements on cardiovascular disease,
7, 8
 RCTs testing the effect of long-term use of low-dose 
calcium supplements on advanced adenoma or colorectal cancer, with additional assessment of 
the risk-benefit balance in terms of colorectal cancer, cardiovascular disease, and osteoporosis 
are warranted.    
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Figure legends 
 
Figure 1. Flowchart for study selection 
Figure 2. Linear dose-response meta-analyses of calcium intakes and adenoma risk.  RR=relative 
risk; CI=confidence interval. (A) Total calcium intake and total adenomas; (B) Total calcium 
intake and adenomas by subtypes; (C) Supplemental calcium intake and total adenomas 
Figure 3. Non-linear dose-response meta-analysis of total calcium intake and adenoma risk 
(reference=550mg/day) (A) Total adenomas (Pnon-linearity<0.01); (B) High-risk adenomas (Pnon-
linearity<0.01). RR=relative risk 
Legend: 
Inner ticks on the x axis represent data points contributed by the studies included in the meta-
analysis   
 
Figure 4. Contour-enhanced funnel plot. 
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Figure 1 
571 publications identified on initial search 
250 PubMed 
321 Embase 
 
413 publications screened based on title and abstract 
         
92 publications assessed based on full-text; 
references were reviewed for additional publications 
 
Overall: 14 publications, corresponding to 14 studies, included 
 
( For total adenomas ): 13 studies 
Primary analysis: 8 prospective studies  
Secondary analysis: 5 retrospective studies 
 
( For high-risk adenomas ): 6 prospective studies 
       -  5 studies from primary analysis 
       -  1 additional study  
 
158 duplicates removed 
 
321 publications excluded  
for not meeting the inclusion criteria 
 
78 publications excluded: 
75 irrelevant topics 
1 duplicate  
2 not eligible for primary dose-response 
meta-analysis 
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Figure 2A 
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Figure 2B 
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Figure 2C 
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Supplementary Table 1. Database Search Strategy 
PubMed (calcium[tw] AND (intake[tw] OR dietary[tw] OR diet[tw] OR food[tw] OR foods[tw] OR 
supplementation[tw] OR supplement[tw] OR supplements[tw])) AND (("Adenomatous 
Polyps"[Mesh] OR "Adenoma"[Mesh] OR adenoma[tw] OR adenomas[tw] OR 
adenomatous[tw] OR "Polyps"[Mesh:NoExp] OR "Intestinal Polyps"[Mesh] OR polyp[tw] 
OR polyps[tw]) AND ("Intestine, Large"[Mesh] OR "Colorectal Neoplasms"[Mesh:NoExp] 
OR "Colonic Neoplasms"[Mesh:NoExp] OR "Rectal Neoplasms"[Mesh:NoExp] OR 
colon[tw] OR rectum[tw] OR colonic[tw] OR rectal[tw] OR colorectal[tw] OR colo 
rectal[tw]))  
Embase ('calcium intake'/de OR (calcium:ab,ti AND (intake:ab,ti OR diet*:ab,ti OR food*:ab,ti OR 
supplement*:ab,ti ))) AND ('colorectal adenoma'/exp OR 'intestine polyp'/exp OR 
('adenoma'/exp OR adenoma:ab,ti OR adeonmas:ab,ti OR adenomatous:ab,ti OR 
polyp*:ab,ti) AND ('large intestine tumor'/exp OR 'colon'/exp OR 'rectum'/exp OR 
colon:ab,ti OR rectum:ab,ti OR colonic:ab,ti OR rectal:ab,ti OR colorectal:ab,ti OR 'colo 
rectal':ab,ti))  
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Supplementary Table 2. Main characteristics of observational studies included in the dose-response meta-analyses 
First 
author, 
Year, 
Country, 
Reference 
Source 
population 
Study 
period 
No. 
cases, 
No. 
controls 
Sex, 
Age 
Total mean 
intake at 
study entry 
(mg/d) 
Adenoma 
outcome  
Calcium type, 
Highest vs. 
lowest 
calcium 
intake 
(mg/d) 
OR/HR  
(95% CI)  Variables adjusted for 
Prospective studies      
Massa, 
2014, 
USA 
16
 
Colonosco
py/sigmoi
doscopy-
based 
 
1991-2007  2,273 
39,130 
 
female 
 
26-60yrs 
1,133 
 
occurrence Total 
1,822 vs. 436 
OR: 0.82 
(0.61, 1.10) 
age, family history of colorectal 
cancer, reason for endoscopy, height, 
BMI, physical activity, smoking, 
aspirin use, UV-B flux, folate, vitamin 
B6, alcohol, unprocessed red meat, 
processed meats, total energy intake 
Yamaji, 
2012, 
Japan 
29
 
 
 
Colonosco
py-based 
 
 
 
2004-2005 
 
 
737 
703 
 
combined 
 
M:50-79yrs 
F:40-79yrs 
570 occurrence Total 
937 vs. 333 
OR: 0.67 
(0.47, 0.95) 
age, screening period, sex, season of 
blood collection, smoking, alcohol, 
BMI, family history of colorectal 
cancer, NSAID use, total energy 
intake, height 
Oh, 
2007, 
USA 
11
 
Sigmoidos
copy-
based 
 
 
1980-2002 
 
2,747 
45,368 
 
female 
 
34-59yrs 
732 occurrence Total 
1,451 vs. 584 
OR: 0.88 
(0.74, 1.04) 
age, BMI, smoking , alcohol, family 
history of colon cancer, history of 
previous endoscopic screening, 
aspirin use, physical activity, 
menopausal status, hormone use, 
total energy intake, fiber, red meat, 
folate, phosphorus, vitamin D  
Kesse, 
2005, 
France 
34
 
E3N-EPIC 
 
(1993-1995) 
to 1997 
 
516 
5,320 
 
female 
 
52.8yrs 
1,035 occurrence  Total 
1,348 vs. 688 
HR: 0.80  
(0.62, 1.03) 
age, sex, educational level, smoking, 
family history of colon cancer, BMI, 
physical activity, total energy intake, 
alcohol 
Hartman, 
2005, 
With prior 
adenomec
1 or 4yrs 
since 
754 
1,151 
 981 recurrence Total 
1,354 vs. 592 
OR: 0.86 
(0.62, 1.18) 
age, NSAID use, sex, total energy 
intake, intervention assignment, sex, 
3

USA 
35
 
tomy 
 
(1991-1994)    
combined  
 
61.1yrs 
intervention group 
   754 
1,151 
  Supplemental 
199 vs. 0 
OR: 0.83 
(0.65, 1.05) 
 
Peters, 
2004, 
USA 
14
 
 
Sigmoidos
copy-
based 
 
 
(1993-2001) 
 to 2003 
3,162 
34,817 
 
combined 
 
55-74yrs  
1,171 occurrence  Total 
2,229 vs. 572 
OR: 0.90 
(0.77, 1.04) 
age, screening center, sex, total 
energy intake, ethnic origin, 
educational level, smoking, alcohol, 
aspirin and ibuprofen use, physical 
activity, BMI, red meat, folate, fiber 
   3,155 
34,811 
  Supplemental 
1,366 vs. 0 
OR: 0.74 
(0.57, 0.95) 
 
Boyapati, 
2003, 
USA 
31
 
Colonosco
py-based 
 
 
1995-1997 
 
 
177 
288 
 
combined 
 
56yrs 
     826 occurrence Total 
1,247 vs. 417 
OR: 0.64 
(0.35, 1.15) 
age, sex, total energy intake 
Lieberman, 
2003, 
USA 
27
 
Colonosco
py-based 
1994-1997 
 
 
312 
1,359 
 
combined 
 
50-75yrs 
     780 occurrence Total 
1,415 vs. 393 
OR: 0.51 
(0.31, 0.83) 
age, total energy intake, family 
history, BMI, smoking, alcohol, 
physical activity, NSAID use 
Martinez, 
2002, 
USA 
36
 
With prior 
adenomec
tomy 
 
3.1yrs 639 
665 
 
NR 
66yrs 
1,062 recurrence Total 
629 vs. 1,638 
OR: 0.62 
(0.42, 0.90) 
age, sex, number of colonoscopies, 
history of polyps prior to baseline, 
aspirin use, fiber, vitamin D, location 
and number of polyps at baseline, 
total energy intake 
   639 
665 
  Supplemental 
300 vs. 0 
OR: 0.94 
(0.67, 1.33) 
 
Retrospective studies 
Fu, 
2012, 
USA 
30
 
Colonosco
py-based 
 
2003-2010 
 
 
1,271 
3,269 
 
combined 
971 occurrence Total 
1,268 vs. 758 
OR: 0.74 
(0.60, 0.90) 
age, sex, study sites, race, 
educational level, indication for 
colonoscopy, recruitment before or 
after colonoscopy, year of  
4

 
  
 
 
 
 
 
   56.8yrs     recruitment, smoking, NSAID use, 
total energy intake 
Miller, 
2007, 
USA 
28
 
Colonosco
py-based 
1998-2000 
 
 
218 
473 
 
combined 
 
56.2yrs 
916 occurrence Total 
1,100 vs. 300 

OR: 0.85  
(0.53, 1.37) 
age, race, sex, total energy intake 
Levine, 
2001, 
USA 
32
 
 
Sigmoidos
copy-
based 
 
 
1991-1993 
 
 
518 
553 
 
combined 
 
61.8yrs 
900 occurrence Total 
1,404 vs. 285 
OR: 1.05 
(0.74, 1.49) 
age, sex, race, clinic, sigmoidoscopy 
date, total energy intake, BMI, fiber, 
saturated fat, multivitamin use 
Tseng, 
1996, 
USA 
15
 
Colonosco
py-based 
 
 
1988-1991 
 
 
237 
783 
 
combined 
 
60.2yrs 
780 occurrence Total 
1,323 vs. 329 
OR: 0.71 
(0.36, 1.38) 
age, BMI, total energy intake, 
smoking, alcohol, supplement use, 
family history of colon cancer, total 
fat, fiber 
Martinez, 
1996, 
USA 
33
 
Colonosco
py/sigmoi
doscopy-
based 
 
 
1991-1993 
 
 
157 
480 
 
combined 
 
54.7yrs 
775 occurrence Total 
1,386 vs. 357 
OR: 0.7 
(0.30, 1.30) 
age, sex, race, BMI, smoking, family 
history, NSAID and aspirin use, fiber, 
total fat 
Abbreviations: BMI, body mass index; F, females; M, males; No., number;  NR, not reported;  NSAID, non-steroidal anti-inflammatory drug; yrs, year 
5

 
Supplementary Table 3. Subgroup analyses for linear dose-response meta-analysis of prospective 
studies 
    Pheterogeneity  
Subgroups 
No. of 
studies RR*(95% CI) I2(%) 
Within 
subgroup 
Between 
subgroups  
All studies 8 0.95 (0.92, 0.98) 45 0.08 NA 
1) By etiologic heterogeneity     
Sites of adenomas      
Distal colorectum 2 0.98 (0.95, 1.01) 28 0.24 0.17 
Entire colorectum 6 0.92 (0.88, 0.96) 26 0.13  
Endpoints of adenomas      
Occurrence 6 0.96 (0.93, 0.99) 34 0.18 0.16 
Recurrence 2 0.89 (0.82, 0.97) 9 0.29  
2) By potential effect modifiers     
Baseline age      
> 60yrs 4 0.93 (0.86, 1.00) 64 0.04 0.98 
 60yrs 4 0.95 (0.93, 0.98) 0 0.45  
Sex      
Women 3 0.95 (0.93, 0.98) 0 0.47 0.74 
Combined 5 0.92 (0.85, 0.99) 60 0.04  
Geographical location     
USA 6 0.95 (0.92, 0.99) 46 0.10 0.21 
Europe 1 0.89 (0.80, 1.00) NA NA  
Asia 1 0.87 (0.74, 1.03) NA NA  
Fortification of dairy products with vitamin D    
Yes 6 0.95 (0.92, 0.99) 46 0.10 0.20 
No 2 0.89 (0.81, 0.97) 0 0.82  
Baseline calcium intake     
> 1000 mg/day 4 0.95 (0.91, 0.99) 67 0.03 0.61 
 1000 mg/day 4 0.94 (0.89, 0.98) 13 0.62  
3) By methodological characteristics     
Measures of association     
Hazard ratio 1 0.89 (0.80, 1.00) NA NA 0.40 
Odds ratio 7 0.95 (0.92, 0.98) 44 0.10  
No. of cases      
> 1000 3 0.97 (0.95, 0.99) 11 0.33 0.03 
 1000 5 0.89 (0.84, 0.94) 0 0.85  
6

Use of validated dietary questionnaire 
Yes 7 0.94 (0.91, 0.97) 12 0.34 0.14 
No 1 0.99 (0.96, 1.01) NA NA  
Adjustment for confounders     
BMI, PA      
Yes 5 0.96 (0.94, 0.99) 34 0.20 0.08 
No 3 0.89 (0.83, 0.95) 0 0.56  
Smoking, Alcohol intake     
Yes 5 0.96 (0.94, 0.99) 34 0.19 0.09 
No 3 0.89 (0.82, 0.96) 0 0.52  
Any vitamin D      
Yes 4 0.94 (0.90, 0.98) 37 0.19 0.69 
No 4 0.94 (0.89, 1.01) 44 0.15  
Intakes of red meat, fiber and folate     
Yes 2 0.98 (0.95, 1.01) 28 0.24 0.17 
No 6 0.92 (0.88, 0.96) 26 0.24  
NSAID use      
Yes 7 0.95 (0.92, 0.98) 44 0.10 0.40 
No 1 0.89 (0.80, 1.00) NA NA  
Family history of colorectal cancer     
Yes 5 0.95 (0.92, 0.98) 0 0.46 0.75 
No 3 0.93 (0.86, 1.02) 70 0.04  
History of endoscopy prior to study entry 
Yes 2 0.91 (0.83, 1.01) 64 0.10 0.49 
No 6 0.96 (0.93, 0.99) 34 0.18  
Abbreviations: BMI, body mass index; NA, not applicable; PA, physical activity; No, number; NSAID, 
non-steroidal anti-inflammatory drug; yr, year 
*RR for a 300mg/day increase in total calcium intake 
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Supplementary Figure 1. 
Overall  (I-squared = 0.0%, p = 0.540)
First author, year
Kampman, 1994*
Oh, 2007
Hyman, 1998*
Hartman, 2005
Kesse, 2005
Massa, 2014
Martinez, 2002
Peters, 2004
0.86 (0.79, 0.94)
RR (95% CI)
1.13 (0.76, 1.67)
0.88 (0.74, 1.04)
0.72 (0.43, 1.21)
0.86 (0.62, 1.19)
0.80 (0.62, 1.03)
0.82 (0.61, 1.10)
0.62 (0.42, 0.91)
0.90 (0.77, 1.05)
  1.4 1.3
RR for highest vs. lowest category
 
* represents the two studies that were not eligible for dose-response meta-analysis due to insufficient 
information 
 
MOOSE Checklist  
 
Criteria Brief description of how the criteria were handled in the 
meta-analysis 
Reporting of background should 
include 
 
 Problem definition While evidence from randomized controlled trials suggests that 
calcium may protect against the recurrence of colorectal 
adenomas, because the trials used only a large dose of 
calcium supplements and were of small sizes, knowledge of 
the dose-response relationship and influence on high-risk 
adenomas is limited. 
 Hypothesis statement Calcium may continue to decrease the risk adenomas, 
particularly high-risk adenomas, over a wide range of calcium 
intake. 
 Description of study outcomes Colorectal adenomas, which precedes the majority of 
colorectal cancers, the third most commonly diagnosed cancer 
and the fourth leading cause of cancer death worldwide, 
excluding non-melanoma skin cancer.   
 Type of exposure or intervention 
used 
Calcium intake (total and supplemental) 
 Type of study designs used We included prospective observational studies for the primary 
analysis. 
 Study population We placed no restriction. 
Reporting of search strategy should 
include 
 
 Qualifications of searchers The credentials of the two investigators DL and NK were 
indicated in the author list.    
 Search strategy, including time 
period included in the synthesis 
and keywords 
Search was done to include studies published up April 2014.     
Detailed search strategy was provided in the supplementary 
material. 
 Databases and registries 
searched 
PubMed and Embase  
 Search software used, name and 
version, including special features 
We did not employ a search software.  
EndNote was used to merge retrieved articles and eliminate 
duplicates. 
 Use of hand searching We hand-searched the reference lists of studies included in 
this analysis and those of selected reviews and meta-analyses. 
 List of citations located and those 
excluded, including justifications 
Details of the literature search process are outlined in Figure1. 
 Method of addressing articles 
published in languages other than 
English 
We restricted the language to English. 
 Method of handling abstracts and 
unpublished studies 
We excluded abstracts and unpublished results.  
 Description of any contact with 
authors 
Authors of two publications were contacted for necessary 
information and one author provided the requested data. 
Reporting of methods should 
include 
 
 Description of relevance or 
appropriateness of studies 
assembled for assessing the 
hypothesis to be tested 
Detailed inclusion and exclusion criteria were described in the 
method section.  
 Rationale for the selection and 
coding of data 
Studies had to provide all the data required for dose-response 
meta-analysis. 
 Assessment of confounding We extracted the most fully adjusted RRs; conducted subgroup 
analyses and meta-regression by adjustment for important 
confounders. 
 Assessment of study quality, 
including blinding of quality 
assessors; stratification or 
regression on possible predictors 
of study results 
Study quality was assessed by conducting subgroup analyses 
and meta-regression by variables concerning methodological 
characteristics. 
 Assessment of heterogeneity Heterogeneity in the relationship between calcium intake and 
the risk of adenomas across studies was assessed by Q test 
and quantified by I
2
. 
 Description of statistical methods 
in sufficient detail to be replicated 
Description of dose-response meta-analysis was detailed in the 
method section. 
 Provision of appropriate tables 
and graphics 
We included two tables (summary characteristics of the studies 
included, summary results from subgroup analyses) and four 
figures (flow chart, linear dose-response meta-analysis, non-
linear dose-response meta-analyses, funnel plot). 
Reporting of results should include  
 Graph summarizing individual 
study estimates and overall 
estimate 
Figure 2  
 Table giving descriptive 
information for each study 
included 
Table 1 
 Results of sensitivity testing 
 
Table 2 
 Indication of statistical uncertainty 
of findings 
95% confidence intervals were presented for all summary 
estimates.    
Reporting of discussion should 
include 
 
 Quantitative assessment of bias Measurement errors are likely to underestimate the true effect, 
but small study effects may have led to overestimation.  Thus, 
some cancellation of biases is expected.    
 Justification for exclusion We excluded retrospective studies to minimize recall and 
selection bias. 
 Assessment of quality of included 
studies 
We reported that none of the methodological aspects was a 
statistically significant source of heterogeneity.   
Reporting of conclusions should 
include 
 
 Consideration of alternative 
explanations for observed results 
Alternative explanations were thoroughly discussed in the 
limitations. 
 Generalization of the conclusions Calcium intake was associated with reduced risk of adenomas, 
particularly high-risk adenomas, over a wide range of calcium 
intake. By preventing adenoma formation, calcium may have 
chemopreventive potential against colorectal neoplasias. 
 Guidelines for future research Future studies had to examine if regular use of low-dose 
calcium supplements leads to protection against colorectal 
cancer, with additional assessment of the risk-benefit balance 
in terms of colorectal cancer, cardiovascular disease, and 
osteoporosis. 
 Disclosure of funding source We declared no external funding for this work in the 
acknowledgement section. 
 
